Health Net Called Her Transplant Experimental. A Riverside Jury Priced the Word at $89.1 Million.

Nelene Fox was 38, a mother of three in Temecula, California, when she was diagnosed with advanced breast cancer in mid-1991. After two mastectomies and chemotherapy, her doctors recommended a bone marrow transplant.

Her health plan said no. The reason it gave was one word: the procedure was experimental.

So her family and her community raised the money and paid for it themselves. She had the transplant. She died on April 22, 1993.

On December 28 of that year, a jury in Riverside County Superior Court put a price on the denial. The number was $89.1 million, and most of it was not compensation at all.

The procedure at the center

The treatment was an autologous bone marrow transplant, which means the patient’s own marrow is collected, very high doses of chemotherapy are given, and the marrow is returned to rebuild the blood system the chemotherapy destroys.

In the early 1990s it was among the most aggressive options available for advanced breast cancer, and it was expensive. Newsweek put the cost at $140,000; the trial summary carried by the family’s co-counsel put it at $150,000.

Health Net, her HMO, classified it as experimental and declined to cover it. A health plan is generally allowed to exclude experimental or investigational treatment, meaning care not yet accepted as standard.

The fight in Fox was never really about whether such an exclusion can exist. It was about how this plan applied it, and who inside the plan had a reason to apply it that way.

The months that did not wait

Cancer sets its own schedule, and a coverage appeal does not move at that speed.

While the denial stood, family members refinanced their homes and church groups held fundraisers. By August 1992, according to Newsweek, the community had raised enough. The transplant happened about eight months after the recommendation.

That gap became part of what the trial was about.

Nelene Fox died on April 22, 1993.

Her brother, Mark Hiepler, was a lawyer. He took the case against Health Net.

What the jury was actually asked

The claim was bad faith breach of contract, which in California means handling a claim unfairly, not merely handling it wrongly.

A plan that reads its own policy incorrectly owes the benefit. A plan that a jury finds acted in bad faith is exposed to punitive damages, which are money awarded to punish rather than to repay.

Newsweek reported that Health Net’s compensation plan offered year-end bonuses to executives who saved on large payouts. The family’s lawyer put it to the jury this way, in the summary carried by co-counsel: “a man who makes the decision on whether you get a procedure gets a bonus on how well the company does financially.”

On December 28, 1993 the jury found for the Fox family.

Two facts underneath the $89.1 million

The verdict is almost always cited as $89 million, and then the story stops.

Two facts sit underneath that figure, and both change what it means.

The first is the split. Of the $89.1 million, $12.1 million was compensatory, for bad faith and reckless infliction of emotional distress. The other $77 million was punitive damages.

That $77 million is not what the treatment cost. It is not what the family lost. It is what a jury decided the conduct was worth punishing by, and it runs to more than 500 times the $150,000 price of the procedure that was refused. That multiple is our arithmetic on the two reported figures.

The second fact is the one that almost never travels with the headline. USA Today reported that Health Net filed a motion for a new trial, then reached a settlement for an undisclosed sum. Time, reporting on a later Health Net case in January 1996, described the Fox award as “later negotiated down to an undisclosed sum.”

The $89.1 million was never a check. It was a verdict that got converted, behind a confidentiality term, into a number the public does not have.

That is the standing shape of these cases. The jury speaks in public. The payment happens in private.

What the case changed, and what it did not

Fox v. Health Net became a reference point in the health plan fights of the 1990s. It was covered nationally, including by Time and Newsweek, and Health Net changed its own procedures in the mid-1990s, a company executive later told the Los Angeles Business Journal: written guidelines on when it would pay for expensive procedures, and an independent panel of medical experts with final say on requests that fell outside them.

There is also a harder fact that belongs in an honest file about this case.

In April 2000, the New England Journal of Medicine published a randomized trial from the Philadelphia Bone Marrow Transplant Group comparing high-dose chemotherapy with stem cell transplant against conventional-dose chemotherapy in women with metastatic breast cancer. Three-year survival was 32 percent in the transplant group and 38 percent in the conventional group, a difference the authors called not significant.

That does not settle the case, and it does not settle the argument. A jury in 1993 was not asked whether the transplant would have saved Nelene Fox. It was asked how the plan behaved toward a dying member with a doctor’s recommendation in hand.

Those are separate questions, and collapsing them is how both sides of this argument tend to cheat.

The word was doing the work

A word in a benefits document, experimental, carried the outcome. It decided whether a family fundraised or filed a claim form. It decided whether a plan paid a $150,000 bill in 1992 or faced a punitive verdict in December 1993.

Health plans still write that exclusion. Experimental and investigational language still sits in coverage documents, still gets applied by people inside the plan, and still gets fought about in state review processes.

Jim Fox, her husband, is quoted in the trial summary on what the family had not done: “The purpose of this was never to get money, or else we would have settled already.”